Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vaccine Development and Evaluation Centre

- PMLiVE

Sanofi begins construction on the first of two Evolutive Vaccine Facilities in Singapore

The two sites aim to improve pandemic preparedness and will have an estimated cost of $1.3bn over the next five years

- PMLiVE

UK government announce £260m to boost healthcare research and manufacturing

This investment will help the NHS deliver new life-saving treatments to patients more efficiently and will help to support more diverse and inclusive clinical research

- PMLiVE

UK expands COVID-19 vaccine plans as winter approaches

The UK government will offer a booster dose of an mRNA COVID-19 vaccine to all adults aged 40 and a second Pfizer/BioNTech shot for 16- and 17-year-olds

- PMLiVE

British officials reportedly monitoring Philip Morris’ proposed acquisition of Vectura

PMI, which owns a portfolio of tobacco products, announced a deal to acquire Vectura for £927m earlier this week

- PMLiVE

UK to provide genomic sequencing globally to identify COVID-19 variants

Public Health England has identified the first group of countries to receive genomic sequencing support through NVAP

- PMLiVE

UK plans to launch new national health agency focused on tackling pandemics

The UK Health Security Agency will protect against future health threats

- PMLiVE

UK and CureVac to jointly develop vaccines against COVID-19 variants

Agreement will utilise UK’s expertise in genomics and CureVac’s experience in mRNA vaccine development

- PMLiVE

UK launches world-first COVID-19 study evaluating a mixed-vaccine regimen

Participants could receive AZ/Oxford University's vaccine for their first dose and Pfizer/BioNTech's vaccine for their second

- PMLiVE

UK vaccinations top nine million as concerns rise over South Africa variant

Surge testing is set to take place in eight areas linked to variant

- PMLiVE

UK orders 40 million additional doses of Valneva’s COVID-19 vaccine

The UK's vaccine portfolio now includes a total of 407 million doses from a number of companies

- PMLiVE

The pandemic preparedness paradox

Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity

- PMLiVE

Valneva launches phase 1/2 COVID-19 vaccine trials in the UK

UK government has pre-ordered 60 million doses of candidate

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links